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Abstract
Background: Treatment plan quality assurance (QA) is important for clinical studies and for institutions aiming
to generate near-optimal individualized treatment plans. However, determining how good a given plan is for
that particular patient (individualized patient/plan QA, in contrast to running through a checklist of generic QA
parameters applied to all patients) is difficult, time consuming and operator-dependent. We therefore evaluated the
potential of RapidPlan, a commercial knowledge-based planning solution, to automate this process, by predicting
achievable OAR doses for individual patients based on a model library consisting of historical plans with a range of
organ-at-risk (OAR) to planning target volume (PTV) geometries and dosimetries.
Methods: A 90-plan RapidPlan model, generated using previously created automatic interactively optimized (AIO)
plans, was used to predict achievable OAR dose-volume histograms (DVHs) for the parotid glands, submandibular
glands, individual swallowing muscles and oral cavities of 20 head and neck cancer (HNC) patients using a
volumetric modulated (RapidArc) simultaneous integrated boost technique. Predicted mean OAR doses were
compared with mean doses achieved when RapidPlan was used to make a new plan. Differences between the
achieved and predicted DVH-lines were analyzed. Finally, RapidPlan predictions were used to evaluate achieved
OAR sparing of AIO and manual interactively optimized plans.
Results: For all OARs, strong linear correlations (R2 = 0.94–0.99) were found between predicted and achieved mean
doses. RapidPlan generally overestimated the amount of achievable sparing for OARs with a large degree of
OAR-PTV overlap. RapidPlan QA using predicted doses alone identified that for 50 % (10/20) of the manually optimized
plans, sparing of the composite salivary glands, oral cavity or composite swallowing muscles could be improved by
at least 3 Gy, 5 Gy or 7 Gy, respectively, while this was the case for 20 % (4/20) AIO plans. These predicted gains were
validated by replanning the identified patients using RapidPlan.
Conclusions: Strong correlations between predicted and achieved mean doses indicate that RapidPlan could
accurately predict achievable mean doses. This shows the feasibility of using RapidPlan DVH prediction alone for
automated individualized head and neck plan QA. This has applications in individual centers and clinical trials.
Keywords: Treatment planning quality assurance, OAR sparing, Knowledge-based planning
* Correspondence: j.tol@vumc.nl
Department of Radiotherapy, VU University Medical Center, De Boelelaan
1117, 1081 HV, Amsterdam, The Netherlands
© 2015 Tol et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Tol et al. Radiation Oncology  (2015) 10:234 
DOI 10.1186/s13014-015-0542-1
Background
The increasing complexity of radiotherapy treatment
planning, particularly due to the attempt to spare more
individual organs-at-risk (OARs), has made it chal-
lenging to efficiently produce consistent, high quality
radiotherapy treatment plans [1, 2]. This has led to
considerable interest in (semi) automated planning strat-
egies [3–9]. Plan quality assurance (QA) is another step
in the treatment preparation workflow that might benefit
from increased automation, since often, insufficient at-
tention is given to evaluating whether a given plan can
be improved. The time consuming [10], difficult and
subjective nature of this process QA makes it hard to be
confident that good plan quality is being obtained for in-
dividual patients. Furthermore, sub-optimal plans sub-
mitted to clinical trials have been correlated with worse
clinical outcomes [11], suggesting that high quality plans
are important for maximizing treatment outcomes.
However, the fact that sub-optimal plans were accepted
to the trial identifies a clear need for a robust and effi-
cient plan QA tool to determine in near real-time
whether plans meet an acceptable quality standard for
individual patients [12]. Although Moore et al. [13] have
recently published an analysis in which the number of
patients at unnecessary risk for normal tissue complica-
tion probability was determined by comparing the pre-
dicted and achieved dosimetry, they used an in-house
developed knowledge-based planning solution [14].
In contrast we have investigated whether OAR dose-
volume histograms (DVH) predicted by RapidPlan™, a
commercial knowledge-based planning solution (Varian
Medical Systems, Palo Alto, USA), are accurate enough
to serve as a plan QA tool that could be used in clinical
departments or for clinical trials. RapidPlan utilizes a
library of plans to construct a model [14–17]. This
model uses the geometrical features and associated dosim-
etry of the plans included in the library to predict a range
of achievable DVH-lines for OARs of new patients. This
range consists of the mean estimated DVH-line ± one
standard deviation. The accuracy of the DVH prediction is
therefore influenced by the consistency of the plans and
the range of patient geometries in the library. The DVH-
lines obtained during treatment planning for a patient can
be compared with the DVHs predicted by RapidPlan. If the
RapidPlan predictions are accurate, this comparison can be
used to determine whether the evaluated plan has achieved
adequate OAR sparing, as judged against the model library.
This approach does not require the creation of additional
plans and it would therefore present a fast and straightfor-
ward solution for plan QA. Although there have been
reports of improvements in OAR sparing using RapidPlan
[5–7], these do not necessarily imply that there was a close
correspondence between the achieved and predicted DVH-
lines, nor has this relationship been evaluated.
Our work differs from previous publications [14, 18]
in several ways, including (i) using a commercial pro-
gram to predict achievable DVHs, (ii) use of complex
head and neck cancer (HNC) treatment plans, involving
sparing of the parotid glands, submandibular glands, oral
cavity and individual swallowing muscles, along with
two PTVs and a simultaneous integrated boost, (iii) de-
tailed evaluation of the relationship between predicted
and achieved dosimetry along the entire DVH-curve,
and (iv) demonstration of QA application by using DVH
predictions generated by RapidPlan to benchmark previ-
ously created plans.
Methods
General description of treatment planning
All HNC plans were created with a simultaneous inte-
grated boost (SIB) technique using 6MV photons and 2
full RapidArc™ (Varian Medical Systems, Palo Alto,
USA) arcs. In 35 fractions, plans aimed to deliver 95 %
of the prescribed dose of 54.25Gy/70.0Gy to 98 %/99 %
of the elective/boost PTV (PTVE/PTVB), while limiting
the volume of each PTV receiving >107 % of the pre-
scribed dose. A 5mm transition zone (PTVT) was cre-
ated between PTVE and PTVB to facilitate dose fall-off
between them. The optimization goals and included
OARs have been outlined in detail previously [7, 19–21].
Model library
Ninety HNC patients treated between 2012 and 2014 were
arbitrarily selected. Primary tumor locations included the
oropharynx (n = 47), (supra-)glottic larynx (n = 25), hypo-
pharynx (n = 10), nasopharynx (n = 2), unknown (n = 2),
thyroid (n = 1) and maxillary sinus (n = 1). Since the goal
was to create a general HNC RapidPlan model, no differ-
entiation was made regarding primary tumor location.
New treatment plans for these patients were created using
our in-house developed automatic interactive optimizer
(AIO). AIO was developed to produce plans with more
consistent OAR sparing than manually optimized
plans by automatically adapting the dose-volume objec-
tives throughout the interactive optimization process, en-
suring that the same level of attention is given to sparing
of each OAR [9]. These plans were created in the Eclipse
treatment planning system using the progressive reso-
lution optimizer (PRO) v10.0.28 and anisotropic analytical
algorithm (AAA) with a 2.5mm grid. The geometric and
dosimetric features of the AIO plans were used to create a
RapidPlan model library. This model could then be used
to predict achievable OAR DVHs for patients outside
the model library, based on their OAR-PTV geometry
(Table 1). RapidPlan automates the optimization process
by generating a line of optimization objectives just below
the inferior boundary of the OAR DVH prediction range.
A standard set of optimization objective priorities,
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reflecting our institutional practice, was used for all pa-
tients. Figure 1 shows the RapidPlan optimization window
with various OARs included. The shaded regions repre-
sent the OAR DVH prediction ranges, while the dotted
lines represent the automatically generated optimization
objectives, placed just below the inferior boundary of the
DVH prediction range. To prevent underdosing of the
PTVs, RapidPlan is designed to place the line objective
horizontally in the OAR-PTV overlap volume. In this
study, line objectives were generated for the parotid glands,
submandibular glands, individual swallowing muscles and
oral cavity, while fixed maximum point dose objectives of
37 Gy and 39 Gy were set for the spinal cord/brainstem
and their planning at risk volumes, respectively.
Replanning of dosimetric outliers
The RapidPlan model configuration window provides
detailed information regarding geometric and dosimetric
outliers that are present in the created model. Although
AIO provides an automated and consistent approach to
OAR dose reduction during the optimization process,
some OARs could still be identified by the model as
providing insufficient sparing. This could for example be
because a trade-off with sparing of other OARs or strict
PTV dose homogeneity criteria prevented better sparing.
The consistency of the plans included in the model was
therefore improved by two iterations of replanning such
dosimetric outliers. In this process, the included OAR
DVHs were compared against the range of achievable
DVHs predicted by the model. A patient was replanned
using RapidPlan if, subjectively judged, a meaningful
Table 1 Summary of the RapidPlan model characteristics for
each individual organ-at-risk (OAR)












Contralateral Parotid 90 - 0.77 1.096
Contralateral
Submandibular
69 - 0.68 1.094
Ipsilateral Parotid 86 - 0.52 1.051
Cricopharyngeal Muscle 52 - 0.75 1.117
Lower Larynx 46 - 0.82 1.125
Upper Larynx 26 36 0.76 1.196
Inferior PCMa 38 48 0.86 1.229
Medial PCMa 24 42 0.58 1.169
Superior PCMa 39 48 0.89 1.128
Upper Esophageal
Spincter
68 - 0.85 1.147
Oral Cavity 76 - 0.80 1.073
Abbreviation: aPCM Pharyngeal constrictor muscle
The model fit R2 value shows the correlation between the geometric and
dosimetric regression parameters. Where relevant, the RapidPlan model
configuration algorithm can suggest to include more OARs in the model
library. This could for example be in the case where there is large variation
in OAR sparing between the plans that are included in the model library.
Including more plans could improve the prediction accuracy. Because not
every structure was attempted to be spared in the original clinical plan, the
number of structures included in the model varies per OAR
Fig. 1 Organ-at-risk (OAR) dose-volume histogram (DVH) prediction ranges (shaded regions) generated by the RapidPlan model and optimization
objectives placed along the inferior DVH prediction boundary (dotted lines). To prevent underdosing of the planning target volume (PTV), line
objectives are placed horizontally in the portion of the OAR that overlaps with the PTV
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improvement in sparing was predicted for at least one
OAR. The RapidPlan model configuration window
assists the user in this process by allowing them to
visualize the predicted and achieved DVHs for all OARs
included in the model. Cleaning the model in this
fashion is intended to improve the consistency of the
included plans and lead to more accurate predictions of
achievable OAR DVHs for new patients.
As an example, Figs. 2a and 3a show two OARs identi-
fied as dosimetric outliers because of a discrepancy be-
tween the predicted DVH range (shaded blue region)
and the achieved DVH (solid blue line), as visualized in
the model configuration window. Figures 2b and 3b
show the resulting DVH-lines after replanning the corre-
sponding patients using the RapidPlan model, resulting
in improved sparing for both OARs and a closer corres-
pondence between the predicted and achieved DVHs.
The residual plots (Figs. 2c and 3c), indicating the rela-
tion between the achieved OAR DVH (y-axis) and the
OAR DVH predicted by the RapidPlan model (x-axis),
also improved after replanning (2d and 3d). In total, 19
and 15 plans containing one or more dosimetric outlier
OARs were replanned in the first and second iteration,
respectively.
Evaluation group for plan quality checking
The evaluation dataset consisted of the contoured
planning CT-scans of 20 HNC patients treated between
2012 and 2013, along with their manual interactively
optimized clinical plans (i.e. plans where the planner
manually adapted the position of the OAR dose-volume
objectives during the optimization process, relative to
the position of the DVH-lines). For the evaluation group,
primary tumors were oropharynx (n = 11), (supra-)glottic
Fig. 2 Example of an upper larynx contained in the RapidPlan model that was identified as a dosimetric outlier in the model configuration
window. Screenshots taken from the RapidPlan model configuration window. The discrepancy between the predicted and achieved dose-volume
histogram (DVH) lines (a) was solved by replanning the corresponding patient (indicated by solid blue line) using the RapidPlan model (b). The
shaded region indicates the DVH prediction range for the selected plan. RapidPlan uses principal component analysis to decompose the shape of
the achieved and predicted DVHs in the model library, allowing for a more consistent way to compare the estimated and obtained dosimetry.
The residual plot (c) shows the correlation between the obtained (DVH principal component score 1) and predicted dosimetry (estimated DVH
principal component score 1) after replanning (d), indicating that the predicted OAR DVH closely corresponds to the OAR DVH included in the
model library. Since more than one upper larynx was identified as an outlier in the two iterations of outlier replanning, more DVHs are noted
to change
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larynx (n = 5), hypopharynx (n = 2), and unknown (n = 2).
These plans were not part of the model library. The
following investigations were performed:
(1). For each OAR spared in the original clinical plan,
the mean dose predicted by the RapidPlan model
was derived by creating a “mid-prediction”
DVH-line running through the middle of the
DVH prediction range (Fig. 4). To determine the
accuracy of the predicted DVH, this mean dose
was compared against the mean dose that was
obtained when a plan was made using the
RapidPlan model.
(2). Because this comparison of mean doses does
not reflect possible differences between the
mid-prediction DVH-line and the achieved
DVH-line, this difference was determined over
the entire dose range.
(3). The mid-prediction DVH-line was used to evaluate
the quality of AIO plans and manually optimized
clinical plans for the 20 patients in the evaluation
group. The manually optimized plans were created
before AIO was introduced in our clinic, and based
Fig. 3 Similar to Fig. 2, an oral cavity identified as an outlier in the RapidPlan model library
Fig. 4 The mid-prediction dose-volume histogram (DVH) line (dashed)
running through the middle of the DVH prediction range (shaded
region). This was used as a surrogate for the prediction DVH in this
study and determined using an in-house developed program coded in
Lazarus (http://www.lazarus.freepascal.org/)
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Fig. 5 (See legend on next page.)
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on prior experience [7], were generally expected to
provide less OAR sparing than the AIO plans. For
illustrative purposes, the plans were considered
acceptable if the mean dose to the composite
(volume weighted) salivary glands, oral cavity and
composite swallowing muscles was no more than
3 Gy, 5 Gy and 7 Gy higher, respectively, than the
mean dose of the mid-prediction DVH-line. These
arbitrary thresholds were chosen to represent
clinically meaningful values. A higher threshold
value was used for the oral cavity because
institutional experience suggest that this structure
is subject to more contouring and geometric
variability. The threshold was highest for the
swallowing muscles because these structures are
relatively small and large dose differences are more
easily obtained when replanning. Since the OAR
DVH prediction by the RapidPlan model takes the
geometrical features of the evaluated patient into
account, this provides a patient specific approach
to plan quality assurance.
Results
Figure 5 shows for the first 3 patients examples of the
DVH prediction range estimated by the RapidPlan
model along with the DVHs that were achieved when
using RapidPlan to create a new treatment plan and the
previously created clinical plan DVHs. For the contralat-
eral parotid and submandibular glands, the achieved
DVHs were relatively comparable for both planning
methods, indicating that the clinical plan spared these
structures comparably to the plans that were included in
the model. More variation is seen for the upper larynx
and oral cavity, where the predicted gains generally were
achieved by RapidPlan. The time required to generate
the DVH predictions was less than 2 min while the
optimization time of the RapidPlan plans was typically
10-15 min.
The maximum dose values to the spinal cord and brain-
stem were found to be clinically acceptable in all plans.
Compared to the manually optimized plans, RapidPlan im-
proved mean composite salivary gland doses by on average
2.0 ± 2.1Gy (range of -2.7 Gy to 6.5 Gy), mean oral cavity
doses by 3.6 ± 3.6Gy (-2.1 Gy to 9.7 Gy) and mean com-
posite swallowing muscle doses by 5.9 ± 2.9 Gy (0.6 Gy to
11.4 Gy). Figure 6 shows the predicted mean dose plotted
against the achieved mean dose for multiple OARs. The
solid line represents a linear fit created through all
datapoints. The dashed line has a slope of 1 and runs
through the origin, meaning that for OARs on this line,
the mean dose that was predicted by RapidPlan was
exactly achieved. All OARs showed a strong linear correl-
ation between predicted and achieved mean doses, with R2
correlation coefficient values ranging from 0.94 for the
contralateral parotid gland to 0.99 for the ipsilateral par-
otid gland. For all OARs combined, the linear fit has a R2
of 0.97, and a slope greater than 1 (1.08). This indicates
that on average, the achieved mean dose was slightly
higher than the mean dose that was predicted by Rapid-
Plan. This was likely caused by several OARs with mean
doses >40 Gy that were located above the dashed fits, indi-
cating that the RapidPlan model overestimated the
amount of OAR sparing that could be achieved. These
OARs consisted of one ipsilateral parotid gland, one crico-
pharyngeal muscle and 6 pharyngeal constrictor muscles,
overlapping with the PTVs by 43 ± 11 %, on average. For
these OARs, RapidPlan was unable to accurately predict
the amount of OAR sparing that was achieved in the por-
tion of the OAR that overlapped with the elective and
boost PTV.
For each OAR, Fig. 7a shows the dose difference
(ΔDose, y-axis), computed as achieved DVH dose minus
mid-prediction DVH dose, plotted against the mid-
prediction DVH dose (x-axis). Series of datapoints can
be noted running through the graph. These datapoints
belong to OARs for which ΔDose changes gradually with
dose. More sudden, larger changes in ΔDose, suggesting
less accurate predictions, can also be noted, for example
in the bottom portion of the graph around 30-40 Gy.
This graph shows that the prediction is generally more
accurate at low OAR doses. At high OAR doses, and
therefore at large overlap volumes with the PTVs,
RapidPlan often overestimated the amount of sparing
that could be achieved (ΔDose values greater than 0).
Figure 7b shows the same ΔDose values at 5 % OAR
volume increments, separated on the basis of the mean
OAR dose achieved in the final RapidPlan plan. For all
OARs, ΔDose is closer to 0 at higher OAR volumes
(typically receiving low doses). At the higher dose
regions (OAR volumes <30 %), the amount of achiev-
able sparing is underestimated for OARs with mean
doses <20 Gy while it is progressively overestimated for
OARs with higher mean doses. This likely resulted from
the horizontal placement of the dose-volume objectives at
the OAR-PTV overlap volume (Fig. 1). Consistent with
this hypothesis, the amount of OAR-PTV overlap for the
(See figure on previous page.)
Fig. 5 Examples of predicted dose-volume histogram (DVH) ranges (shaded regions) and achieved DVH-lines for multiple organs-at-risk (OARs) of
three patients. The solid lines represent the DVHs that were achieved in the previously created clinical plans, while the dotted lines indicate the
DVHs that were obtained when the RapidPlan model was used to create a new treatment plan. The mid-prediction DVH-line used for the analysis
in the present report is located in the middle of the shaded region
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OARs with achieved mean doses of <20 Gy, 20-30 Gy,
30-40 Gy and >40 Gy was 1.2 ± 2.0 %, 7.7 ± 7.0 %,
19.8 ± 9.8 % and 35.9 ± 11.9 %, respectively.
The OAR DVH predictions generated by the RapidPlan
model were used to re-evaluate the quality of the 20
manually optimized clinical plans, benchmarked using the
mean dose of the mid-prediction DVH-line. 10 plans were
found acceptable and provided sparing of the composite
salivary glands, oral cavity and composite swallowing mus-
cles at most 3 Gy, 5 Gy and 7 Gy higher than the mean
dose of the mid-prediction DVH-line generated for these
structures, respectively. Figure 8 shows the predicted and
achieved mean dose values of the clinical plans that passed
(green circles) and failed (red circles) these criteria, com-
bined with the linear fits between predicted and achieved
RapidPlan mean dose shown in Fig. 6. The small number
of points located below the fit indicate that for the major-
ity of OARs, the RapidPlan model improved OAR sparing
over the clinical plan. Using the same thresholds, 4 AIO
plans did not pass the QA, all because of inferior oral cav-
ity sparing. The salivary glands and swallowing muscles
were within the chosen thresholds for OAR sparing in all
AIO plans. As expected from the high R2 values, after re-
planning of the patients that violated the criteria using
RapidPlan, all resulting OAR mean doses fell within the
respective threshold range from the predicted mean doses.
Discussion
This study assessed the potential to use OAR DVH pre-
dictions generated by a RapidPlan model to evaluate the
dosimetric quality of plans that were not included in the
model. For all OARs, strong correlations were found be-
tween mean OAR doses predicted by the model and
mean doses achieved after the model was used to guide
the creation of a new treatment plan, with linear fit
slopes close to one. This means that in general, achiev-
able OAR mean doses could be determined in advance
by using the model solely to predict DVHs, without
requiring the creation of an actual treatment plan.
Although previous investigations showed the potential of
RapidPlan to improve plan quality [5–7], the present
study is the first to evaluate the accuracy of the dosimet-
ric predictions. This is relevant because improved plan
quality does not necessarily imply that accurate predic-
tions were generated, whilst accurately modeling achiev-
able OAR doses is an important prerequisite for using
RapidPlan as a plan QA tool. The prediction accuracy
was determined for mean OAR doses because such
doses have been shown to correlate to late toxicity for
HNC patients [22–26].
Since the created RapidPlan model was found able to
accurately predict the achievable mean OAR doses
(Fig. 6), it could be used to evaluate the quality of previ-
ously created (manually optimized) clinical plans. Under
the test conditions, this suggested that 50 % of the evalu-
ated plans contained a composite OAR for which the
sparing could be improved. These predicted gains in
plan quality were not unexpected since the RapidPlan
model was made using an AIO plan library, and AIO
plans have been previously shown to provide improved
OAR sparing over manual interactively optimized plans,
along with being optimized in a more consistent fashion
(9). Consistent with this, only 4/20 AIO plans were
rejected because oral cavity sparing could have been
improved, while salivary gland and swallowing muscle
sparing was acceptable in all plans. The predicted im-
provements in plan quality were validated by replanning
the patient using the RapidPlan model. The agreement
was consistent with the high R2 values between the
predicted and achieved mean OAR doses, and thus dem-
onstrated successful application of RapidPlan-predicted
DVH metrics as a QA tool. It is important to note that
the high-level correlation between predicted and
achieved dosimetry also allows the RapidPlan model to
be used to evaluate the plans included in the model
library. Replanning sub-optimal plans would allow for
the continuous and consistent improvement of the
model library and the resulting plan quality.
Although on average, RapidPlan could accurately pre-
dict mean doses, predictions could deviate in the high-
dose regions for OARs with both low (<20 Gy) and high
(>40 Gy) mean doses (Fig. 7). For the latter, RapidPlan
overestimated the amount of achievable OAR sparing,
probably because RapidPlan placed the line objective
horizontally in the region of OAR-PTV overlap. In
plans with multiple dose levels, OARs that only overlap
with the lower dose PTV get no optimization objectives
to restrict doses above the prescribed dose for this PTV
(Fig. 1). Although this may not be as important in or-
gans where toxicity is correlated with mean OAR dose,
it could be an issue when high dose volumes are con-
sidered predictors of toxicity. If in future releases of
RapidPlan, line objectives are also modeled for the part
of the OAR that overlaps with the PTV, correlations
(See figure on previous page.)
Fig. 6 For multiple organs-at-risk (OARs), the correlation between predicted (x-axis) and achieved (y-axis) mean OAR doses. The solid lines represent fits
created through all datapoints, while the dashed line indicates a linear fit through the origin. The R2 values indicates the goodness-of-fit of the solid
line with the datapoints. For conciseness, some individual swallowing muscles and the contralateral, and ipsilateral submandibular gland are analyzed
together in these graphs. The number of OARs included in these graphs can vary depending on whether they were designated to be spared in the
original clinical plan
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Fig. 7 The prediction accuracy of RapidPlan along the dose-volume histogram (DVH) line. a Dose difference between the achieved and predicted
DVH-line (ΔDose, y-axis) plotted against the dose of the predicted DVH-line (x-axis). b Box-whisker plots of ΔDose as a function of organ-at-risk
(OAR) volume (x-axis) for four different ranges of OAR mean doses. Lower OAR volumes are typically associated with high doses
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between predicted and achievable OAR DVHs should
improve.
Clinical trials often include treatment plans submitted
by a large number of institutes. The difficulty of deter-
mining whether sufficient OAR sparing is reached for
individual patients may lead to the inclusion of poor
treatment plans, even though the magnitude of achieved
OAR sparing may influence the outcome of the study
[11, 27]. RapidPlan models that consist of a wide range
of patient plans in which a consistently good level of
OAR sparing was reached allow for fast, patient-specific
evaluation of OAR DVHs for plans submitted to the
study. Figure 9 suggests a workflow to quickly decide
whether a submitted plan provides sufficient sparing
based on its OAR-PTV geometry. In addition, the
present results show the feasibility for clinical trials to
supply participating centers with a RapidPlan model to
ensure that all created plans are according to the speci-
fied guidelines. It is important to note that the validity
of a RapidPlan model needs to be re-evaluated when
dose prescriptions or optimization priorities change over
time. Trial-specific model libraries may be required de-
pending on the planning criteria.
Accurate DVH predictions made by RapidPlan models
could similarly be used to benchmark the quality of
plans that were created using alternative delivery tech-
niques, such as proton therapy [28], without requiring
the creation of photon plans. A comparable study was
recently performed that evaluated the potential of an
IMRT model from one institute and made using one
IMRT technique to aid IMRT planning of another insti-
tute and predict achievable DVHs with another IMRT
technique [18]. They found that a fixed gantry model
could accurately predict the median dose of the parotid
gland in Tomotherapy plans, which indicated that it was
spared similarly by both institutions. In addition, predic-
tions of median dose reductions to some OARs in the
Tomotherapy plans could be achieved after replanning.
Potential limitations of the current study include the
following. RapidPlan indicated that for some swallowing
muscles, more training cases containing these structures
were required to improve the model (Table 1). This may
have influenced the predicted and obtained mean doses.
All plans included in the model were created using the
same number of arcs, and similar collimator angles and
field sizes for most plans. If plans created using different
field settings are evaluated, RapidPlan may predict OAR
doses that are only realizable after changing the field
settings. Additionally, different optimization and dose
calculation algorithms were used to create the plans con-
tained in the RapidPlan model library (PRO and AAA
v10.0.28) and the RapidPlan plans (photon optimizer [PO]
and AAA v13.5.33). Small improvements in OAR sparing
when using newer algorithms were found previously [7].
Part of the gains achieved by RapidPlan may therefore be
attributed to the use of the newer optimization and dose
calculation algorithms, and in effect, the RapidPlan model
predictions slightly underestimated the gains that could be
(See figure on previous page.)
Fig. 8 The organs-at-risk (OARs) of the clinical plans that passed (green circles) and failed (red circles) the evaluation criteria, along with the linear
fit between the RapidPlan predicted and achieved mean dose found in Fig. 6. Thresholds of 3 Gy, 5 Gy and 7 Gy were used for quality evaluation
of the composite (volume-weighted) salivary glands, oral cavity and composite swallowing muscles, respectively. Datapoints of individual OARs
with similar predicted and achieved mean doses could still fail the criteria because the analysis was done based on composite OARs
Fig. 9 A flowchart proposing how the organ-at-risk (OAR) dose-volume histogram (DVH) predictions generated by a RapidPlan model could be
used for fast plan quality assurance (QA) for clinical trials
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achieved. Although our study showed good correlations
between achieved and predicted OAR doses, determining
the optimality of the plans included in the model library
or of the resulting plans was beyond the scope of the
present study. Future studies could incorporate retro-
spective RapidPlan QA of completed clinical trials. If a
RapidPlan model were to be used as a planning QA tool
for clinical trials, time and effort would need to be
invested to ensure appropriate model composition and
quality. Finally, if changes in treatment planning tech-
niques lead to improvements in plan quality, these im-
proved plans would need to be incorporated into updated
RapidPlan libraries to ensure that the QA model remained
state of the art, and of sufficiently high quality.
Conclusions
The present study showed that RapidPlan models can ac-
curately predict achievable mean doses for most OARs,
enabling them to be used to benchmark the quality of
existing plans. However, the predictions may be less accur-
ate for OARs that overlap substantially with the PTVs and
may not accurately reflect the shape of the DVH-line. Ad-
dressing these limitations should improve the prediction
accuracy and the potential of RapidPlan for plan quality
assessment.
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